Welcome to our dedicated page for Talphera SEC filings (Ticker: tlph), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vNantahala Capital Management-linked funds acquired 4,266,211 pre-funded warrants to purchase Talphera common stock at $0.585 per warrant, with an exercise price of $0.001 per share. These warrants are exercisable indefinitely, bringing the reporting group’s total to 18,822,267 warrants held indirectly. Nantahala, Wilmot B. Harkey, and Daniel Mack may be deemed beneficial owners but each disclaims ownership beyond their pecuniary interest.
Talphera, Inc. completed the third closing of a previously arranged private placement, raising approximately $4.1 million in gross proceeds from institutional investors and a member of management.
The funding came through unregistered sales of common stock and pre-funded warrants under Section 4(a)(2) and Regulation D. Under a related registration rights agreement, Talphera agreed to file resale registration statements for the shares and warrant shares within 15 days of each closing and to use reasonable best efforts to have them declared effective, including a 90-day outside date following a full SEC review.
Talphera, Inc. reported that Nasdaq has notified the company it is out of compliance with the exchange’s minimum bid price rule, which requires a closing bid of at least $1.00 per share for 30 consecutive business days. The company’s Nasdaq Capital Market listing is not immediately affected.
Talphera has 180 calendar days, until September 7, 2026, to regain compliance by maintaining a closing bid of at least $1.00 for ten consecutive business days. If it fails to do so, it may qualify for an additional 180-day period or face potential delisting if it cannot demonstrate a viable plan to cure the deficiency.
Talphera, Inc. chief executive officer Vincent J. Angotti reported several equity transactions in company stock. On February 12, 2026, he made an open-market purchase of 105,364 shares of common stock at $0.8123 per share, increasing his direct ownership.
That same day, he received a grant of stock options for 594,000 shares, which vest over four years, with one quarter vesting on the one-year anniversary of the grant and the remainder vesting in 36 monthly installments. On February 10 and 14, 2026, a total of 12,738 shares of common stock were surrendered to cover tax withholdings tied to restricted stock unit vesting. After the February 14 tax-withholding disposition, his direct common stock holdings were 577,395 shares, which include a non-reportable acquisition of 10,000 shares through the company’s employee stock purchase plan.
TALPHERA, INC. Chief Medical Officer Aslam Shakil reported two insider transactions. He was granted a stock option covering 205,000 shares of common stock at an exercise price of $0.0000 per share. One fourth of this option vests on the one-year anniversary of the February 12, 2026 grant date, with the remaining shares vesting in 36 equal monthly installments, subject to continued service. On the same date, he also purchased 35,000 shares of common stock in the open market at $0.8123 per share, bringing his direct common stock holdings to 83,178 shares and his option holdings to 205,000 shares.
TALPHERA, INC. Chief Engineering Officer Badri N Dasu reported multiple equity transactions. On February 12, 2026, he purchased 35,000 shares of common stock at $0.8123 per share in an open-market transaction and received a stock option for 200,000 shares of common stock. The option was granted at an exercise price of $0.0000 and will vest over four years, with one quarter vesting on the one-year anniversary of the grant and the remainder vesting in 36 equal monthly installments.
On February 10 and 14, 2026, a total of 3,127 shares of common stock were surrendered in tax-withholding dispositions related to vesting restricted stock units, as noted in the footnote describing shares surrendered to cover required tax withholdings. Following these transactions, Badri N Dasu directly owned 73,884 shares of common stock in one of the reported positions, reflecting his ongoing equity stake in the company.
TALPHERA, INC. Chief Financial Officer Raffi Asadorian reported multiple equity transactions in company stock. He purchased 45,000 shares of common stock in an open-market transaction at $0.8123 per share and now holds a larger direct share position.
He was also granted a stock option for 260,000 shares of common stock, with one quarter vesting on the one-year anniversary of the February 12, 2026 grant and the rest vesting monthly over three years while he remains in service. In separate moves tied to restricted stock unit vesting, he surrendered 2,933 shares and 958 shares of common stock to cover required tax withholdings, leaving 88,323 shares directly owned after the latest tax-related disposition.
Talphera, Inc. received an updated ownership filing showing that investor Laurence W. Lytton and the Lytton-Kambara Foundation together report beneficial ownership of 2,730,718 shares of Talphera common stock, or 5.9% of the company.
Both reporting persons have shared voting and shared dispositive power over these shares, with no sole power to vote or dispose. The percentage is based on 46,609,618 shares outstanding as of November 5, 2025, as cited from Talphera’s Form 10-Q. They certify the holdings were not acquired to change or influence control of Talphera.
Rosalind Advisors and affiliates have filed an amended Schedule 13G reporting a sizable passive stake in Talphera, Inc. common shares. Rosalind Advisors Inc., Rosalind Master Fund L.P., and portfolio managers Steven Salamon and Gilad Aharon report beneficial ownership of 13,150,954 Talphera common shares, representing 9.9% of the class based on 46,609,618 shares outstanding as of November 5, 2025.
The position consists of 3,579,273 common shares plus additional shares issuable from warrants and pre‑funded warrants, some of which are subject to a 9.99% ownership blocker. The reporting persons certify the holdings are in the ordinary course of business and not for the purpose of influencing control.
Talphera, Inc. received an updated ownership disclosure showing that AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman together beneficially own 4,661,502 shares of Talphera common stock, representing 9.8% of the outstanding class as of the event date.
The filing notes rights to purchase an additional 5,454,545 common shares in a second closing, but these are not currently exercisable because of beneficial ownership limits. The reporting persons state the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Talphera.